Market Spotlight: Eating Disorders

  • ID: 4533534
  • Report
  • Region: Global
  • 35 pages
  • Datamonitor Healthcare
1 of 4

FEATURED COMPANIES

  • Edgemont Pharmaceuticals
  • Shire
  • MORE
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • Worldwide. The author estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in young females aged 10-19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
  • The author forecasts the number of prevalent cases of eating disorders to increase to 38.1 million prevalent cases by 2026.
  • The approved drugs in the eating disorders space comprise Edgemont Pharmaceuticals’ Fluoxetine Tablets and Shire’s Vyvanse (lisdexamfetamine dimesylate). These are administered via the oral route, with Vyvanse also available in an intranasal formulation.
  • There are only three drugs in active clinical development for eating disorders, with two drugs in Phase II, and one in Phase III. Therapies in mid-to-late-stage development for eating disorders focus on targets such as dopamine reuptake, norepinephrine reuptake/transporter, opioid receptors, and ghrelin receptor. These drugs are administered via the subcutaneous, oral, and intranasal routes.
  • High impact upcoming events for drugs in the eating disorders space comprise topline Phase II trial results for OPNT001. There have been only two licensing and asset acquisition deals involving eating disorders drugs during 2013-18, both of which occurred in 2017.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for eating disorders have been in the late phase of development, with 82% of trials in Phase III and only 18% of trials in Phase II.
  • Clinical trial activity in the eating disorders space is dominated by completed trials. Shire has the highest number of completed clinical trials for eating disorders, with five trials.
  • Shire leads industry sponsors with the highest number of clinical trials for eating disorders, four of which are in Phase III.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Edgemont Pharmaceuticals
  • Shire
  • MORE

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT
Psychotherapy
Medications

EPIDEMIOLOGY

MARKETED DRUGS
Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY

APPENDIX

List of Figures
Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10-19 years, 2017-26
Figure 2: Overview of pipeline drugs for eating disorders in the US
Figure 3: Pipeline drugs for eating disorders, by company
Figure 4: Pipeline drugs for eating disorders, by drug type
Figure 5: Pipeline drugs for eating disorders, by classifications
Figure 6: Key upcoming events in eating disorders
Figure 7: Licensing and asset acquisition deals in eating disorders, 2013-18
Figure 8: Clinical trials in eating disorders
Figure 9: Top 10 drugs for clinical trials in eating disorders
Figure 10: Top 10 companies for clinical trials in eating disorders
Figure 11: Eating disorders trials status
Figure 12: Eating disorders trials sponsors, by phase

List of Tables
Table 1: Worldwide prevalent cases of eating disorders in females aged 10-19 years, 2017-26
Table 2: Prevalent cases of eating disorders in females aged 10-19 years in Africa, 2017-26
Table 3: Prevalent cases of eating disorders in females aged 10-19 years in Asia, 2017-26
Table 4: Prevalent cases of eating disorders in children aged 10-19 years in Latin America and the Caribbean, 2017-26
Table 5: Prevalent cases of eating disorders in children aged 10-19 years in Northern America, 2017-26
Table 6: Prevalent cases of eating disorders in children aged 10-19 years in Oceania, 2017-26
Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017-26
Table 8: Marketed drugs for eating disorders
Table 9: Approvals by country for eating disorders
Table 10: Pipeline drugs for eating disorders in the US
Table 11: Parent patents in eating disorders
Table 12: Historical global sales, by drug ($m), 2012-17
Table 13: Forecasted global sales, by drug ($m), 2018-22

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Edgemont Pharmaceuticals
  • Shire
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll